NCT05222555 2026-01-16
MINDway
Incyte Corporation
Phase 1/2 Active not recruiting
Clinical Trials
4 trialsNCT04661007 2025-12-18
J-MIND
Incyte Corporation
Phase 1/2 Active not recruiting
NCT05455697 2025-12-18
Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
University of Washington
Phase 1/2 Recruiting
NCT04607772 2025-10-03
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc
Phase 1/2 Withdrawn